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Propranolol in the treatment of an extensive 
facial and orbital infantile hemangioma: case 
report
Abstract
An infantile hemangioma, a common benign vascular tumor of infancy, can cause significant visual function im-
pairment and/or relevant disfigurement. We report the successful outcome with oral propranolol treatment, with 
no adverse events related to the treatment, in a 2-month-old boy who presented with a complicated extensive 
infantile hemangioma of the right hemiface with deep intraorbital involvement, extending to the middle cranial 
fossa and pterygopalatine fossa.
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INTRODUCTION
Infantile hemangiomas are the most common benign 
vascular tumors of infancy. It has an incidence of 1 to 3% 
in newborns and 10 to 12% in children up to the first year of 
life. They are more common in Caucasian children, in females 
(female:male ratio of 3:1) and in premature infants (up to 
30%). The diagnosis is based on clinical history and physical 
examination. Most hemangiomas have an uncomplicated 
benign and dynamic clinic course. Characteristically, they 
undergo a proliferative phase with significant growth and a 
rapidly increasing size of the lesion for several months, usually 
during the first year of life. After this period, there is a gradual 
involution phase, with a slow spontaneous regression over 
several years. It is estimated that the complete regression occurs 
at a rate of 10% per year, so that 30% would completely regress 
up to the age of 3 years, 50% up to the age of 5 years, 70% up 
to the age of 7 years and 90% up to the age of 9 years. On the 
other hand, an important minority of them may be associated 
with significant morbidity in early childhood. The most 
frequently involved regions of the body are the head and neck 
(up to 60%), followed by the trunk (25%) and the extremities 
(15%). Amblyopia, anisometropia, strabismus, proptosis, globe 
dystopia, exposure keratopathy and compressive neuropathy 
can be present in cases involving the eyelid and/or the orbit. 
Therefore, problematic facial lesions can cause severe visual 
impairment and/or relevant disfigurement, and require a 
therapeutic intervention (1). 
Recently, propranolol has become increasingly popular 
as a successful treatment choice for complicated infantile 
hemangiomas, with few side effects comparing with other known 
therapies, namely systemic or intralesional corticosteroids, 
chemotherapeutic agents (vincristine, cyclophosphamide, 
alpha-interferon), radiotherapy, laser therapy, embolization, 
surgical intervention or a combination of treatments (2-4). 
CASE REPORT
A 2-month-old boy was examined for an expansive 
hemangioma of the right hemiface, involving the subcutaneous 
tissue with superficial repercussion on the malar region and 
near the labial commissure. He had experienced progressive 
painless proptosis, superior and lateral displacement of the 
right ocular globe, along with fullness of the inferior eyelid for 
1 month (figure 1).
Figure 1. 2-months-old boy, before treatment. 
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Figure 2. Coronal T2-weighted FSE craniofacial-orbital MRI images, 
before treatment. 
Figure 3. Axial T2-weighted FSE craniofacial-orbital MRI images, 
before treatment. 
Figure 4. Gadolinium-enhanced T1-weighted SPGR craniofacial-
orbital MRI, before treatment.
The assessment by magnetic resonance imaging 
(MRI) revealed a major deep intraorbital component, and a 
subcutaneous inferior periorbital component. It showed a 
voluminous intra and extraconal mass replacing the orbital fat, 
occupying almost the entire orbital cavity with higher expression 
on the medial and inferior aspect. The mass enwrapped the 
ocular globe posteriorly, the extraocular muscles and the optic 
nerve. It was found to spread to the middle cranial fossa through 
the superior orbital fissure; to the pterygopalatine fossa through 
the inferior orbital fissure; and to the eyelids anteriorly, with 
inferior predominance (figures 2-4). 
A partial limitation of opening the right eye was noted. 
No relative afferent pupillary defect was detected. On ocular 
examination performed under general anesthesia, the anterior 
segment was normal, a mean corneal diameter of 10,5 mm was 
measured in both eyes; intraocular pressure were 20 mm Hg 
in the right eye and 18 mm Hg in the left eye, measured by the 
Perkins tonometer; and dilated fundus examination was normal 
in both eyes. 
A detailed and extensive study was conducted, initially 
and during the frequent follow-up visits as required, including 
blood, urinary, imaging and others investigations, following 
a multidisciplinary approach, concerning evaluation and 
monitoring by several specialties (Departments of Pediatrics 
and Neonatology, Ophthalmology, Dermatology – Pedro 
Hispano Hospital, Porto; Departments of Pediatrics/Section of 
Haemato-Oncology, Pediatric Cardiology, Pediatric Surgery – 
São João Hospital, Porto). 
Along with the craniofacial and orbital MRI assessment, 
others exams were managed. They were performed initially and 
repeated as required. A blood biochemistry and haematological 
profile, including a reticulocyte count and iron profile; a 
coagulation study; a urinary biochemistry and sediment; 
serologic and viral markers; a chest radiograph; abdominal, 
renal and pelvic ultrasounds; an electrocardiogram; an 
echocardiogram; an electroencephalogram; and visual evoked 
potentials; all were evaluated and no relevant findings were 
found.
No relevant systemic findings were found, aside from a 
right inguinal hernia corrected with a surgical intervention at 
the age of 6 months. 
No record of relevant family or prenatal history.
At this time, with 2-months-old, he began treatment with 
systemic corticosteroids (prednisolone 2,5 mg/Kg/day).
At 5-months-old, the persistence of a major intraorbital 
component was found in a MRI reassessment, despite the 
relative improvement of the subcutaneous component. After 
the initial course of 3 months of systemic corticosteroids, 
this fact was considered an unsatisfactory clinical outcome, 
therefore oral propranolol treatment was started (2 mg/Kg/day, 
3id) by gradual dose escalation. Systemic corticosteroids were 
gradually tapered, with complete suspension at 7 months of 
age.
Oral propranolol treatment was instituted initially on an 
inpatient setting, taking into account a rigid protocol established 
by the Departments of Pediatrics/Section of Haemato-Oncology 
and Pediatric Cardiology, at São João Hospital, Porto. Posteriorly, 
it was continued on an outpatient basis, also considering strict 
guidelines given to the parents. The outpatient follow-up visits 
were performed every 2-4 weeks by the pediatricians and every 
4-8 weeks by the ophthalmologists, both of them initially more 
frequent. 
At the 9-week follow-up visit after initiation of 
propranolol treatment and after the complete suspension of 
the corticosteroid therapy, the superficial component was 
significantly reduced in size and the proptosis less apparent. 
At 24 months of age, 19 months after the initiation of 
propranolol treatment, a successful clinical and imaging outcome 
was registered. The hemangioma progressively regressed and 
disappeared, documented through MRI evaluation (figures 5-7). 
The ophthalmological examination was considered normal. The 
Hirschberg and Brückner tests were normal. A normal fixation 
behavior was noted through the CSM method (Central, Steady, 
Maintain). 
The cover tests and the assessment of eye movements were 
normal. Another ocular examination performed under general 
anesthesia was carried out: the anterior segment was normal; 
intraocular pressure was 12 mm Hg in both eyes, measured by 
the Perkins tonometer; and dilated fundus examination was 
normal in both eyes. 
Propranolol was discontinued through gradual tapering 
over a 2-month period.
During these 19 months of propranolol treatment, there 
was an attempt to lower the oral dosage, but the failure to 
show regression was noticed on an imaging reassessment at the 
thirteenth month of treatment, so the total oral dosage (2 mg/
kg/day) was re-instituted. 
There were no adverse events related to the treatment. 
Currently, at the age of 3 years, he is on clinical surveillance 
every 4-6 months, and ten months after the discontinuation 
of propranolol treatment, no rebound growth was registered 
and the ophthalmological examination was considered normal. 
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Figure 5. 24-months-old boy, after treatment.
Figure 6. T2-weighted FSE craniofacial-orbital MRI images, after 
treatment.
Figure 7. Gadolinium-enhanced T1-weighted craniofacial-orbital 
MRI images, after treatment. 
DISCUSSION
Since 2008 when for the first time it was reported the efficacy 
of propranolol in inhibiting the growth and controlling the prolife-
rative phase of problematic hemangiomas (2), some reports have 
been published that included hemangiomas with orbital involve-
ment (6-9), but to the authors knowledge none was described as 
having the characteristics and extension of this portuguese case.
Such cases with deep orbital involvement may not be mana-
geable with local therapies like intralesional corticosteroids injec-
tion, laser therapy or surgical intervention, given the potential risk 
of injury to the ocular globe, the extra-ocular muscles and the op-
tic nerve. Systemic pharmacologic treatment with corticosteroids or 
chemotherapeutic agents may be associated with significant adverse 
events, with increased likelihood considering the duration of treatment.
The therapeutic effect of propranolol on hemangiomas, 
which are composed of a complex mixture of clonal endothelial 
cells (associated with intersticial cells as pericytes, dendritic cells 
and mast cells), is thought to be related with three different me-
chanisms: vascoconstriction, inhibition of angiogenesis and induc-
tion of apoptosis.
Epinephrine can cause both vasoconstriction and vasodilata-
tion by activating both the α1 and β2 receptors, respectively. Pro-
pranolol has a β-blocker effect, without the α-antagonistic effect, 
and so inhibits the epinephrine mediated vasodilation, resulting in 
the vasoconstriction of endothelial cells. A clinical improvement is 
immediately visible as a change in color associated with a palpable 
softening of the hemangioma.
During the growth phase of hemangiomas, two major proan-
giogenic factors are involved and have their expression increased: 
basic fibroblast growth factor (bFGF) and vascular endothelial 
growth factor (VEGF). Still in this phase, histological studies have 
shown that both endothelial and interstitial cells are actively di-
viding. Some studies demonstrated that β-blockers can decrease 
the expression of bFGF and VEGF genes, which leads to the in-
hibition of angiogenesis, and thus might explain the progressive 
improvement of the hemangioma.
Apoptosis is a feature of the involution phase of hemangio-
mas. It is regulated by various pathways, with the probable invol-
vement of the β1 adrenergic receptor. It has been hypothesized 
that the blockage of this β1 adrenoreceptor by propranolol, tri-
ggers apoptosis of capillary endothelial cells at an increased rate. 
This molecular mechanism might also explain the progressive im-
provement of the hemangioma.
Hypoglicemia, bradycardia, hypotension and bronchoes-
pasm are well known potential side effects of propranolol, a non 
selective beta-blocker. They all can be adequately managed, fulfi-
lling an initial pediatric assessment before initiation of therapy and 
monitoring such parameters throughout therapy with frequent 
pediatric follow-up visits (2-5). 
In current literature, the duration of treatment with pro-
pranolol ranges widely, between 3 and 18 months, and supports 
discontinuation of therapy through gradual tapering at the end of 
the course over a 2-week period, to minimize the risk of a hypera-
drenergic withdrawal response (5-10). In our patient, therapy was 
continued until complete resolution, treatment for 19 months, 
and propranolol was tapered through a 2-months period, given 
the registered fact of failure to obtain progressive regression at 13 
months of treatment, during an attempt to lower the propranolol dose.
The successful outcome with no side effects in this patient, 
avoiding severe visual impairment during the critical period of vi-
sual development, supports the effectiveness of oral propranolol 
treatment for problematic hemangiomas, and possibly as a first 
line treatment in these cases.
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